• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)

      Discover Clario's AI solutions, where innovation meets expertise. Since 2018, we have revolutionized clinical trial endpoint analyses with more than 30 AI-enabled solutions across 600+ active trials, enhancing data quality and patient privacy while expediting data collection processes.

      Go to page
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials

      All the precision endpoint technology and services your virtual or hybrid trial needs to deliver more certain outcomes.

      Go to page
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Neuroscience
    • Dermatology
    • Oncology
    • Gastroenterology
    • Ophthalmology
    • Hepatology
    • Respiratory Solutions
    • Infectious Diseases
    • Type 2 Diabetes and Obesity
    • Musculoskeletal
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Researcher spotlight: Lori Quinn

Researcher spotlight: Lori Quinn

Precision Motion

March 12, 2025

Lori Quinn, PT, EdD, FAPTA

Professor, Motor Learning and Control Program Department of Biobehavioral Studies, Teachers College at Columbia University

Opal V2R® technology has been used by thousands of researchers worldwide, and together, these researchers have published more than 750 peer reviewed papers, greatly contributing to the available body of evidence in human movement.

APDM is a part of Clario, a leading provider of endpoint data solutions to the clinical trials industry. For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world.

The Opal V2R® solution has been utilized to assess human movement across more than 30 therapeutic indications providing richer insights and meaningful outcomes. Unlock the full potential of your research with Opal V2R® technology.

For more information, visit our Wearable Biosensors for Research page. 

Q:

Would you please introduce yourself, your academic background and your research interests?

A:

I am Professor in the Motor Learning and Control Program, Department of Biobehavioral Studies, at Teachers College, Columbia University. I received a BS in physical therapy from the University of Connecticut in 1989 and an Ed.D. in Movement Sciences from Teachers College in 1996. I am currently the director of the Neurorehabilitation Research Lab at Teachers College, and my research has focused on movement-based evaluations and interventions for people with neurodegenerative diseases, including people with Huntington’s disease and Parkinson’s disease. My work incorporates use of wearable devices for digital-based assessments.

Q:

Do you have a personal story that led to your interest in human movement/ neurodegenerative disease research? What continues to drive your ambitions as a scientist?

A:

I have a strong desire to develop evidence-based interventions for people with neurodegenerative diseases. Having sensitive measures of gait and mobility are critical to testing the efficacy of physical activity interventions, particularly in the early disease stages. I am also driven by my students, who ask great questions and motivate me to be a better clinical researcher.

Q:

How has Clario’s APDM Opal V2R® System been most useful in your research endeavors?

A:

We have used Clario’s APDM Opal sensors to evaluate measures of gait, mobility and postural control in individuals with Huntington’s disease, stroke and Parkinson’s disease. We have identified several measures of postural sway and mobility that were most sensitive as early markers of disease in people with HD.

Q:

What research projects or questions are you currently working on?

A:

We are extending on previous work in Huntington’s disease on a project called Balance-HD. We are collaborating with Nora Fritz, PT, DPT, PhD Wayne State University; Lisa Muratori, Stony Brook University; and Deb Kegelmeyer and Anne Kloos, Ohio State University to validate measures of balance in individuals with Huntington’s disease across disease stages using clinical measures as well as APDM Opal sensors. We hope to identify measures that can be used as clinical trial endpoints, both for physical activity and exercise interventions, as well as pharmacological and gene-based therapies. We are also using APDM sensors in a study in Parkinson’s disease, evaluating functional mobility in various transitional tasks. This study is being conducted by two of my doctoral students – Jehan Alomar and Lilliana Romero.

Q:

Where do you see the use of wearable IMU’s in human movement research going in the next 5 years?

A:

I believe wearable IMUs will be ubiquitous in clinical research, and importantly will help us provide sensitive measures of mobility not just in the clinic but in daily living environments. I hope we will move to more consistently evaluating individuals in their homes and communities as means to track disease progression and identify motor impairments earlier.

Q:

Fill in the blank: When I’m not working on a research project, you can find me…

A:

Playing golf! I recently took up golf and am obsessed with mastering this skill! And enjoying time with my husband and two daughters.

Check out some of this researcher’s recent publications

Peer-Reviewed

Measures of postural control and mobility during dual-tasking as candidate markers of instability in Huntington’s disease

Read

Learn more about Opal wearable sensors or be featured in an upcoming researcher spotlight

Contact Clario Precision Motion
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Article

Transforming clinical trials with AI

SCOPE speaking session

Read
Article

The power of clinical adjudication

Enhancing clinical trial success

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum